Abstract: The present invention provides novel bisindolylmaleimide, indolylmaleimide, triphenylethylene and bisindolylpyra-zolone compounds for use in methods of treating fat cell associated diseases such as obesity, liposarcoma and polycystic ovary syndrome (PCOS) by targeting adipocytes while minimizing hERG blocker (QTc prolongation) activity. The fluoro substituted secondary amino analogs and prodrugs of the present invention are an effective approach by which properties of these compounds such as drug pharmacokinetics, pharmacodynamics and toxicology can be modulated.